Glenmark Pharmaceuticals Has Entered Into An Exclusive Agreement

Glenmark Pharmaceuticals has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm. Co. Ltd. to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada.

"Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorisations and commercialise the products in North America," the company said in a BSE filing.

Glenmark Pharmaceuticals President, North America & Global API, Robert Matsuk said, the agreement for these ophthalmic products is aligned with the company's strategy to strengthen its focus on complex generic formulations.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory